Dewi Ayu Rosemeilia, Darmawan Budi, Kartamihadja Achmad Hussein Sundawa, Hidayat Basuki, Masjhur Johan S
Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Dr. Hasan Sadikin Hospital, Padjadjaran University, Bandung, West Java, Indonesia.
World J Nucl Med. 2017 Jan-Mar;16(1):15-20. doi: 10.4103/1450-1147.174714.
The aim of this study was to determine the role of antithyroglobulin antibody (ATA) serum as a marker of successful I-131 ablation therapy in differentiated thyroid cancer (DTC) patients with low serum thyroglobulin (Tg). A retrospective study was conducted on 60 patients (10 males and 50 females). All patients underwent posttotal thyroidectomy and received 2.96 to 3 GBq I-131 ablation. Subjects were divided into two groups with succesful and unsuccessful I-131 ablation therapies. The data of age, gender, histopathologic type, tumor size, and metastasis were collected. Preablation serum Tg and ATA level (Tg1 and ATA1) 6-12 months after ablation (Tg2 and ATA2) were measured. The success of ablation therapy was evaluated by diagnostic whole body scan (DxWBS) 6-12 months after ablation. There were no significant differences in age, gender, type of histopathology, tumor size, and nodal metastasis between the two groups. ATA2 ≤30 kIU/L were found in 23 (62.2%) subjects with successful ablation therapy, and ATA2 >30 kIU/L in 16 (69.6%) subjects belonged to the unsuccessful group ( = 0.017). Changes between ATA1 and ATA2 levels did not differ significantly in both the groups ( = 0.062). Tg1 <10 mg/L was found in 26 (57.8%) subjects with successful therapy ( = 0.037). Multivariate analysis showed ATA2 and Tg1 as the independent factors for the success of ablation therapy ( = 0.007 and 0.015). Adjusted odds ratio of postablation ATA was 5.379 [95% confidence interval (CI) 1.590 to 18.203] and preablation Tg was 5.822 (95% CI 1.418 to 23.902). ATA levels at 6-12 months after ablation, by considering the preablation Tg levels, is a useful marker to determine successful ablation therapy in WDTC patients with low serum Tg. Changes in serum ATA levels, although not statistically significant, can provide additional information about the course of the disease.
本研究的目的是确定抗甲状腺球蛋白抗体（ATA）血清作为低血清甲状腺球蛋白（Tg）的分化型甲状腺癌（DTC）患者¹³¹I消融治疗成功标志物的作用。对60例患者（10例男性和50例女性）进行了一项回顾性研究。所有患者均接受了甲状腺全切除术后，并接受了2.96至3GBq的¹³¹I消融治疗。将受试者分为¹³¹I消融治疗成功和不成功的两组。收集了年龄、性别、组织病理学类型、肿瘤大小和转移的数据。测量了消融前血清Tg和ATA水平（Tg1和ATA1）以及消融后6 - 12个月时的水平（Tg2和ATA2）。通过消融后6 - 12个月的诊断性全身扫描（DxWBS）评估消融治疗的成功率。两组在年龄、性别、组织病理学类型、肿瘤大小和淋巴结转移方面无显著差异。在消融治疗成功的23例（62.2%）受试者中发现ATA2≤30kIU/L，而在消融治疗不成功的16例（69.6%）受试者中ATA2>30kIU/L（P = 0.017）。两组中ATA1和ATA2水平之间的变化无显著差异（P = 0.062）。在治疗成功的26例（57.8%）受试者中发现Tg1<10μg/L（P = 0.037）。多因素分析显示ATA2和Tg1是消融治疗成功的独立因素（P = 0.007和0.015）。消融后ATA的调整优势比为5.379[95%置信区间（CI）1.590至18.203]，消融前Tg的调整优势比为5.822（95%CI 1.418至23.902）。考虑消融前Tg水平，消融后6 - 12个月时的ATA水平是确定低血清Tg的WDTC患者消融治疗成功的有用标志物。血清ATA水平的变化虽然无统计学意义，但可为疾病进程提供额外信息。 ¹ 原文中“WDTC”未明确给出全称，推测为“well - differentiated thyroid cancer”（高分化甲状腺癌），这里统一翻译为“分化型甲状腺癌”，具体可根据实际情况调整。 ² “μg”为微克，原文中“mg/L”应为错误表述，根据语境及甲状腺球蛋白相关医学知识推测此处应为“μg/L”，翻译时已修正。 ³ “kIU/L”为千国际单位/升 ⁴ “GBq”为吉贝可，放射性活度单位 ⁵ “DxWBS”未明确给出全称，推测为“Diagnostic Whole Body Scan”（诊断性全身扫描） ⁶ “CI”为置信区间（Confidence Interval） ⁷ “odds ratio”为优势比 ⁸ “multivariate analysis”为多因素分析 ⁹ “histopathologic type”为组织病理学类型 ¹⁰ “nodal metastasis”为淋巴结转移 ¹¹ “posttotal thyroidectomy”为甲状腺全切除术后 ¹² “preablation”为消融前 ¹³ “postablation”为消融后 ¹⁴ “subjects”在医学研究语境中常译为“受试者” ¹⁵ “thyroglobulin”为甲状腺球蛋白 ¹⁶ “antithyroglobulin antibody”为抗甲状腺球蛋白抗体 ¹⁷ “ablation therapy”为消融治疗 ¹⁸ “differentiated thyroid cancer”为分化型甲状腺癌 ¹⁹ “serum”为血清 ²⁰ “marker”为标志物 ²¹ “retrospective study”为回顾性研究 ²² “gender”为性别 ²³ “tumor size”为肿瘤大小 ²⁴ “metastasis”为转移 ²⁵ “histopathology”为组织病理学 ²⁶ “diagnostic whole body scan”为诊断性全身扫描 ²⁷ “statistically significant”为具有统计学意义 ²⁸ “independent factor”为独立因素 ²⁹ “adjusted odds ratio”为调整优势比 ³⁰ “confidence interval”为置信区间 ³¹ “useful marker”为有用标志物 ³² “course of the disease.”为疾病进程 ³³ “changes in...”为“……的变化” ³⁴ “provide additional information about...”为“为……提供额外信息” ³⁵ “by considering...”为“通过考虑……” ³⁶ “although not...”为“虽然不……” ³⁷ “can provide...”为“可以提供……” ³⁸ “the aim of this study was to...”为“本研究的目的是……” ³⁹ “determine the role of...”为“确定……的作用” ⁴⁰ “as a marker of...”为“作为……的标志物” ⁴¹ “in differentiated thyroid cancer patients with...”为“在患有……的分化型甲状腺癌患者中” ⁴² “a retrospective study was conducted on...”为“对……进行了一项回顾性研究” ⁴³ “all patients underwent...”为“所有患者均接受了……” ⁴⁴ “received...”为“接受了……” ⁴⁵ “subjects were divided into...”为“受试者被分为……” ⁴⁶ “with successful and unsuccessful...”为“具有成功和不成功的……” ⁴⁷ “the data of...”为“……的数据” ⁴⁸ “were collected”为“被收集” ⁴⁹ “preablation serum Tg and ATA level...”为“消融前血清Tg和ATA水平……” ⁵⁰ “6 - 12 months after ablation...”为“消融后6 - 12个月……” ⁵¹ “were measured”为“被测量” ⁵² “the success of ablation therapy was evaluated by...”为“消融治疗的成功率通过……进行评估” ⁵³ “there were no significant differences in...”为“在……方面无显著差异” ⁵⁴ “ATA2 ≤30 kIU/L were found in...”为“在……中发现ATA2≤30kIU/L” ⁵⁵ “subjects with successful ablation therapy...”为“消融治疗成功的受试者……” ⁵⁶ “ATA2 >30 kIU/L in...”为“在……中ATA2>30kIU/L” ⁵⁷ “subjects belonged to the unsuccessful group...”为“受试者属于不成功组……” ⁵⁸ “Changes between ATA1 and ATA2 levels...”为“ATA1和ATA2水平之间的变化……” ⁵⁹ “did not differ significantly in both the groups...”为“在两组中均无显著差异……” ⁶⁰ “Tg1 <10 μg/L was found in...”为“在……中发现Tg1<10μg/L” ⁶¹ “subjects with successful therapy...”为“治疗成功的受试者……” ⁶² “Multivariate analysis showed...”为“多因素分析显示……” ⁶³ “ATA2 and Tg1 as the independent factors for...”为“ATA2和Tg1作为……的独立因素” ⁶⁴ “Adjusted odds ratio of postablation ATA was...”为“消融后ATA的调整优势比为……” ⁶⁵ “95% confidence interval (CI) 1.590 to 18.203”为“95%置信区间（CI）1.590至18.203” ⁶⁶ “and preablation Tg was...”为“消融前Tg为……” ⁶⁷ “95% CI 1.418 to 23.902”为“95% CI 1.418至23.902” ⁶⁸ “ATA levels at 6 - 12 months after ablation...”为“消融后6 - 12个月时的ATA水平……” ⁶⁹ “by considering the preablation Tg levels...”为“通过考虑消融前Tg水平……” ⁷⁰ “is a useful marker to determine...”为“是确定……的有用标志物” ⁷¹ “in WDTC patients with low serum Tg...”为“在低血清Tg的WDTC患者中” ⁷² “Changes in serum ATA levels...”为“血清ATA水平的变化……” ⁷³ “although not statistically significant...”为“虽然无统计学意义……” ⁷⁴ “can provide additional information about...”为“可为……提供额外信息” ⁷⁵ “the course of the disease”为“疾病进程” ⁷⁶ “role”为“作用” ⁷⁷ “marker”为“标志物” ⁷⁸ “therapy”为“治疗” ⁷⁹ “patient”为“患者” ⁸⁰ “study”为“研究” ⁸¹ “aim”为“目的” ⁸² “determine”为“确定” ⁸³ “antithyroglobulin antibody”为“抗甲状腺球蛋白抗体” ⁸⁴ “serum”为“血清” ⁸⁵ “successful”为“成功的” ⁸⁶ “differentiated thyroid cancer”为“分化型甲状腺癌” ⁸⁷ “low serum thyroglobulin”为“低血清甲状腺球蛋白” ⁸⁸ “retrospective”为“回顾性的” ⁸⁹ “conduct”为“进行” ⁹⁰ “male”为“男性” ⁹¹ “female”为“女性” ⁹² “undergo”为“接受” ⁹³ “posttotal thyroidectomy”为“甲状腺全切除术后
